One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Bringing Harm Reduction into Health Policy — Combating the Overdose Crisis
Kimberly L. Sue, M.D., Ph.D., and David A. Fiellin, M.D.
doi : 10.1056/NEJMp2103274
N Engl J Med 2021; 384:1781-1783
The Number Needed to Prescribe — What Would It Take to Expand Access to Buprenorphine?
Elisabeth Poorman, M.D., M.P.H.
doi : 10.1056/NEJMp2101298
N Engl J Med 2021; 384:1783-1784
Detained
Merlys Rodriguez-Hernandez, M.D., Tara C. Pilato, B.A., Kayleigh A. Yerdon, B.S., Ian M. Kysel, J.D., L.L.M., Faten Taki, Ph.D., Stephen Yale-Loehr, J.D., Gunisha Kaur, M.D., illustrated by Alison E. Burke, M.A., and Natalie Koscal, M.A.
doi : 10.1056/NEJMp2032690
N Engl J Med 2021; 384:1785-1787
Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media
Alejandro Hoberman, M.D., Diego Preciado, M.D., Ph.D., Jack L. Paradise, M.D., David H. Chi, M.D., MaryAnn Haralam, M.S.N., C.R.N.P., Stan L. Block, M.D., Diana H. Kearney, R.N., C.C.R.C., Sonika Bhatnagar, M.D., M.P.H., Gysella B. Mu?iz Pujalt, M.D., Timothy R. Shope, M.D., M.P.H., Judith M. Martin, M.D., Daniel E. Felten, M.D., Marcia Kurs-Lasky, M.S., Hui Liu, M.S., Kristin Yahner, M.S., Jong-Hyeon Jeong, Ph.D., Norman L. Cohen, M.D., Brian Czervionke, M.D., Jennifer P. Nagg, R.N., Joseph E. Dohar, M.D., and Nader Shaikh, M.D., M.P.H.
doi : 10.1056/NEJMoa2027278
N Engl J Med 2021; 384:1789-1799
Official recommendations differ regarding tympanostomy-tube placement for children with recurrent acute otitis media.
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow, M.D., Jonathan Corren, M.D., Arnaud Bourdin, M.D., Geoffrey Chupp, M.D., Elliot Israel, M.D., Michael E. Wechsler, M.D., Christopher E. Brightling, F.Med.Sci., Janet M. Griffiths, Ph.D., ?sa Hellqvist, M.Sc., Karin Bowen, M.Sc., Primal Kaur, M.D., Gun Almqvist, M.Sc., Sandhia Ponnarambil, M.D., and Gene Colice, M.D.
doi : 10.1056/NEJMoa2034975
N Engl J Med 2021; 384:1800-1809
Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The efficacy and safety of tezepelumab in patients with severe, uncontrolled asthma require further assessment.
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia
Enrico Tiacci, M.D., Luca De Carolis, M.D., Edoardo Simonetti, M.D., Monia Capponi, M.D., Achille Ambrosetti, M.D., Eugenio Lucia, M.D., Agostino Antolino, M.D., Alessandro Pulsoni, M.D., Samantha Ferrari, M.D., Pier L. Zinzani, M.D., Stefano Ascani, M.D., Vincenzo M. Perriello, M.D., Luigi Rigacci, M.D., Gianluca Gaidano, M.D., Roberta Della Seta, M.D., Natalia Frattarelli, M.D., Paolo Falcucci, M.D., Robin Foà, M.D., Giuseppe Visani, M.D., Francesco Zaja, M.D., and Brunangelo Falini, M.D.
doi : 10.1056/NEJMoa2031298
N Engl J Med 2021; 384:1810-1823
Hairy-cell leukemia (HCL) is a CD20+ indolent B-cell cancer in which a BRAF V600E kinase–activating mutation plays a pathogenetic role. In clinical trials involving patients with refractory or relapsed HCL, the targeting of BRAF V600E with the oral BRAF inhibitor vemurafenib led to a response in 91% of the patients; 35% of the patients had a complete response. However, the median relapse-free survival was only 9 months after treatment was stopped.
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
Jerald Sadoff, M.D., Mathieu Le Gars, Ph.D., Georgi Shukarev, M.D., Dirk Heerwegh, Ph.D., Carla Truyers, Ph.D., Anne M. de Groot, Ph.D., Jeroen Stoop, Ph.D., Sarah Tete, Ph.D., Wim Van Damme, M.D., Isabel Leroux-Roels, M.D., Pieter-Jan Berghmans, M.D., Murray Kimmel, D.O., Pierre Van Damme, M.D., Jan de Hoon, M.D., William Smith, M.D., Kathryn E. Stephenson, M.D., Stephen C. De Rosa, M.D., Kristen W. Cohen, Ph.D., M. Juliana McElrath, M.D., Emmanuel Cormier, Ph.D., Gert Scheper, Ph.D., Dan H. Barouch, M.D., Jenny Hendriks, Ph.D., Frank Struyf, M.D., Macaya Douoguih, M.D., Johan Van Hoof, M.D., and Hanneke Schuitemaker, Ph.D.
doi : 10.1056/NEJMoa2034201
N Engl J Med 2021; 384:1824-1835
Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.
Management of the Difficult Airway
Thomas Heidegger, M.D.
doi : 10.1056/NEJMra1916801
N Engl J Med 2021; 384:1836-1847
Herpes-Associated Erythema Multiforme
Mario Puerta-Pena, M.D., and Virginia Velasco-Tamariz, M.D.
doi : 10.1056/NEJMicm2033090
N Engl J Med 2021; 384:1848
Thyrotoxic Periodic Paralysis
Michael Fralick, M.D., Ph.D., and Shohinee Sarma, M.D., M.P.H.
doi : 10.1056/NEJMicm2030770
N Engl J Med 2021; 384:e71
Case 14-2021: A 64-Year-Old Woman with Fever and Pancytopenia
Michael D. Gibbons, M.D., Dexter P. Mendoza, M.D., Anem Waheed, M.D., M.P.H., Miriam B. Barshak, M.D., and Julian A. Villalba, M.D.
doi : 10.1056/NEJMcpc2100275
N Engl J Med 2021; 384:1849-1857
Management of Recurrent Acute Otitis Media
Ellen R. Wald, M.D.
doi : 10.1056/NEJMe2104952
N Engl J Med 2021; 384:1859-1860
Audio Interview: Vaccination and Variants in the U.S. and South Africa
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Glenda E. Gray, M.B., B.Ch., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2108162
N Engl J Med 2021; 384:e85
Deconstructing Inequities — Transparent Values in Measurement and Analytic Choices
Marjory L. Givens, Ph.D., Keith P. Gennuso, Ph.D., Elizabeth A. Pollock, Ph.D., and Sheri L. Johnson, Ph.D.
doi : 10.1056/NEJMms2035717
N Engl J Med 2021; 384:1861-1865
New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
doi : 10.1056/NEJMc2100362
N Engl J Med 2021; 384:1866-1868
Inhaled Treprostinil in Group 3 Pulmonary Hypertension
doi : 10.1056/NEJMc2103465
N Engl J Med 2021; 384:1869-1872
Antithrombotic Therapy after Acute Coronary Syndromes
doi : 10.1056/NEJMc2103789
N Engl J Med 2021; 384:1872-1874
I Can’t Breathe during Interviews — The Incomplete Penetrance of Antiracism
Shakkaura Kemet, M.P.H.
doi : 10.1056/NEJMpv2104827
N Engl J Med 2021; 384:e72
